- Home
- SXTP vs ALZN Comparison
SXTP vs ALZN Comparison
Compare SXTP & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- ALZN
- Stock Information
- Founded
- SXTP 2010
- ALZN 2016
- Country
- SXTP United States
- ALZN United States
- Employees
- SXTP N/A
- ALZN N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- SXTP Health Care
- ALZN Health Care
- Exchange
- SXTP Nasdaq
- ALZN Nasdaq
- Market Cap
- SXTP 3.0M
- ALZN 6.9M
- IPO Year
- SXTP 2023
- ALZN 2021
- Fundamental
- Price
- SXTP $1.04
- ALZN $1.64
- Analyst Decision
- SXTP Buy
- ALZN
- Analyst Count
- SXTP 2
- ALZN 0
- Target Price
- SXTP $28.80
- ALZN N/A
- AVG Volume (30 Days)
- SXTP 87.5K
- ALZN 361.1K
- Earning Date
- SXTP 11-18-2024
- ALZN 12-13-2024
- Dividend Yield
- SXTP N/A
- ALZN N/A
- EPS Growth
- SXTP N/A
- ALZN N/A
- EPS
- SXTP N/A
- ALZN N/A
- Revenue
- SXTP $441,255.00
- ALZN N/A
- Revenue This Year
- SXTP $267.05
- ALZN N/A
- Revenue Next Year
- SXTP $181.82
- ALZN N/A
- P/E Ratio
- SXTP N/A
- ALZN N/A
- Revenue Growth
- SXTP 12.07
- ALZN N/A
- 52 Week Low
- SXTP $0.92
- ALZN $1.40
- 52 Week High
- SXTP $18.36
- ALZN $33.00
- Technical
- Relative Strength Index (RSI)
- SXTP 39.03
- ALZN 40.84
- Support Level
- SXTP $0.92
- ALZN $1.58
- Resistance Level
- SXTP $1.38
- ALZN $1.90
- Average True Range (ATR)
- SXTP 0.11
- ALZN 0.14
- MACD
- SXTP 0.01
- ALZN 0.05
- Stochastic Oscillator
- SXTP 26.72
- ALZN 39.53
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.